Clinical Impact of Initiation of U-500 Insulin vs Continuation of U-100 Insulin in Subjects With Diabetes | Zendy

Alejandro Ramirez | Zendy; Natalia Weare-Regales | Zendy; Anthony Domingo | Zendy; Arnaldo Villafranca | Zendy; Krystal A Valdez | Zendy; C Marcela Velez | Zendy; Philip Foulis | Zendy; Joaquin Gomez-Daspet | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical Impact of Initiation of U-500 Insulin vs Continuation of U-100 Insulin in Subjects With Diabetes

Author(s) -

Alejandro Ramirez,

Natalia Weare-Regales,

Anthony Domingo,

Arnaldo Villafranca,

Krystal A Valdez,

C Marcela Velez,

Philip Foulis,

Joaquin Gomez-Daspet

Publication year - 2021

Publication title -

federal practitioner

Language(s) - English

Resource type - Journals

eISSN - 1945-337X

pISSN - 1078-4497

DOI - 10.12788/fp.0105

Subject(s) - medicine , insulin , hypoglycemia , diabetes mellitus , incidence (geometry) , dose , obesity , insulin resistance , endocrinology , physics , optics

The prevalence of obesity and diabetes mellitus (DM) has each increased drastically according to the Centers for Disease Control and Prevention. Growth of severe insulinresistant DM is predicted. U-500 insulin is highly concentrated and can replace less concentrated formulations in patients that need high insulin dosages. The aim of this study was to compare clinical outcomes of U-500 and U-100 insulin regimens in veterans with obesity and insulin resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research